A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to determine the rate of improvement in objective tumor response,
following the addition of ranpirnase to ongoing pemetrexed-carboplatin chemotherapy, for
patients with SD or PR following 2 cycles of doublet chemotherapy.